Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04799275
Title	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	diffuse large B-cell lymphoma follicular lymphoma lymphoplasmacytic lymphoma diffuse large B-cell lymphoma germinal center B-cell type B-cell lymphoma diffuse large B-cell lymphoma activated B-cell type extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue marginal zone lymphoma
Therapies	Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate
Age Groups:	senior
Covered Countries	USA